In the first half of the year, the volume of pharmaceutical financing fell in price, and investors' safe havens were no longer

more than a year since investment and financing "cooled down", medicine has been recognized as the best safe haven, but a newly released set of data suggests that the "harbour" may not be as safe as people think.
According to the latest set of domestic pharmaceutical bio-investment and financing statistics released recently by China Investment Group, the amount and total amount of financing in the pharmaceutical and biological sector have fallen sharply from a year earlier, with the amount of investment disclosed as financing falling by more than 40%.pharmaceutical biology also had a "winter
a surprising result for the average investor, but it seemed reasonable to professionals who have been investing in medicine for years.
year, he invested in six medical programs, including blood biopsies, genetic testing and molecular diagnostics, an industry insider who has long been involved in investments in the pharmaceutical industry told First Financial. But this year, even after eight months, the number of projects thrown out is still zero.
"has been watching this year, always afraid to spend money. Surrounding peers are also in this state, on the one hand, good projects become less, on the other hand, high-quality projects rise ship high, the price becomes very expensive. The investor said.
his judgment can be seen in the above statistics. Financing events, disclosed financing events and financing volumes have all declined by varying degrees over the past eight months, with the largest decline in the volume of financing, with a 33.68 per cent decline in total volume and a 41.84 per cent decline in the amount disclosed, almost blocking the cut. In contrast, a 27 per cent rise in single funding suggests that good projects are becoming scarce.
Further observation data, in January-August 2016 announced the amount of financing of 82 cases of financing, the PE stage of the case reached 44 cases, accounting for more than 50%, mainly the main board listed companies and the new three board companies after the listing of financing, but belongs to the VC stage of financing, only 38 cases. Investors are becoming cautious about investing and financing early projects.
, the first financial reporter in the industry to discuss this phenomenon has a similar answer. At this stage, the decline in the number of investment may be only a short-term phenomenon, as a long-term layout of the representative areas, pharmaceutical industry investors believe that as long as there are good projects or choose to win, will not be affected by the short-term market environment.
", it's normal for us investors to invest in early projects in five, seven, 10, 15 or even 20 years. Nor will we affect the overall investment layout due to some short-lived market changes. "In China's 20 years of investment, we have had a number of success stories starting from scratch, including biopharmaceuticals, medical devices, and diabetes-related pharmaceutical companies," Oberd, senior managing partner for Asia at Stadt Capital, told First Financial. The entire healthcare industry in China is currently emerging and changing, including its services, innovation, technology and information development, so we need to have a long-term vision and vision for the industry. " sub-sectors are the most popular?"
in terms of the number of financing cases in each sub-sector of this statistic, medicine, medical equipment and medical services are in the top three, with the current hot biotechnology ranking fourth.
, medical devices grabbed the largest piece of cake, with a total financing of $1,592 million. In fact, not only in the domestic market, but also in the domestic pharmaceutical listed companies and other capital investment in overseas projects, medical devices and equipment is currently the most concentrated, most active sub-sectors.
"at this stage we do some investment layout, will also be combined with the future "13th Five-Year Plan" to see. "In fact, you can see that throughout the next five years of planning, the whole field of biomedicine is very focused, which is now the focus of many medical investors layout, in addition to private medical, Chinese medicine, as well as the layout of the integrated payment security system to establish these areas. " (First Financial Weekly)